Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group

Oncology ◽  
2009 ◽  
Vol 77 (2) ◽  
pp. 107-112 ◽  
Author(s):  
Dimosthenis V. Skarlos ◽  
Eleni Timotheadou ◽  
Eleni Galani ◽  
Epaminondas Samantas ◽  
Irene Grimani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Adjuvant Chemotherapy ◽  
Case Control Study ◽  
Case Control ◽  
Oncology Group ◽  
Matched Case ◽  
Dose Dense ◽  
Matched Case Control Study ◽  
Control Study

Light at Night Exposure and Breast Cancer Risk: A Matched Case-Control Study in England

2018 ◽  
Vol 2017 (1) ◽  
pp. 851
Author(s):  
Susan Hodgson ◽  
Anna Freni Sterrantino ◽  
Alianore Descours ◽  
Amanda Cross ◽  
Adi McCrea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Light At Night ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals Erratum: Associations between Dietary Allium Vegetables and Risk of Breast Cancer: A Hospital-Based Matched Case-Control Study

2018 ◽  
Vol 21 (2) ◽  
pp. 231 ◽  
Author(s):  
Ali Pourzand ◽  
Aynaz Tajaddini ◽  
Saeed Pirouzpanah ◽  
Mohammad Asghari-Jafarabadi ◽  
Nasser Samadi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Allium Vegetables ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals Circulating Carnitine Levels and Breast Cancer: A Matched Case-Control Study

2021 ◽  
Author(s):  
Jiayi Zhang ◽  
Gang Wu ◽  
Hailong Zhu ◽  
Fengyuan Yang ◽  
Shuman Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Epidemiologic Studies ◽  
Female Breast Cancer ◽  
False Discovery Rates ◽  
Increased Risk ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Abstract Background: The existing epidemiologic studies on the association between carnitine and breast cancer development are scarce. This study examined the association between circulating carnitine levels and breast cancer in females.Methods: This 1:1 age-matched case-control study identified 991 female breast cancer cases and 991 female controls without breast cancer. All cases and controls were confirmed with a pathological test. We measured 16 types of whole blood carnitine levels, such as free carnitine (C0) and octadecanoylcarnitine (C18), using targeted metabolomic technology. Results: The average age for cases and controls were 50.0 years (SD: 8.7 years) and 49.5 years (SD: 8.7 years), respectively. After adjusting for covariates, each SD increase in malonylcarnitine (C3DC; OR 0.91; 95% CI 0.83-1.00), decenoylcarnitine (C10:1; OR 0.87; 95% CI 0.79-0.96) and decadienoylcarnitine (C10:2; OR 0.90; 95% CI 0.82-0.99) level was associated with decreased odds of breast cancer. However, higher butyrylcarnitine (C4) levels were associated with increased risk of breast cancer (OR 1.12; 95% CI 1.02-1.23). We observed no relationship between other carnitines with breast cancer. The false discovery rates for C3DC, C4, C10:1 and C10:2 were 0.172, 0.120, 0.064 and 0.139, respectively. Conclusions: Higher levels of C3DC, C10:1, and C10:2 were protective factors for breast cancer, whereas increased C4 levels were a risk factor for breast cancer.

scholarly journals 216P The impact of pregnancy-associated breast cancer (PABC) according to immunohistochemical (IHC) subtype: A matched case-control study

2020 ◽  
Vol 31 ◽  
pp. S327
Author(s):  
W. Muñoz-Montaño ◽  
C. De la Garza-Ramos ◽  
A. Tabares ◽  
P. Cabrera-Galeana ◽  
V. Perez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Matched Case ◽  
Subtype A ◽  
The Impact ◽  
Matched Case Control Study ◽  
Control Study

Matched case control analysis of breast cancer specific factors impacting risk of developing SARS-Cov-2 infection.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18579-e18579
Author(s):  
Joanna Zurko ◽  
Aniko Szabo ◽  
Yee Chung Cheng ◽  
Sailaja Kamaraju ◽  
John Burfeind ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Logistic Regression ◽  
Triple Negative ◽  
Case Control Study ◽  
Conditional Logistic Regression ◽  
Case Control ◽  
Control Analysis ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

e18579 Background: Patients with cancer have increased risk of developing SARS-Cov-2 (COVID-19) infection. It is unknown if characteristics related to breast cancer increase the risk of COVID-19 infection. In this retrospective matched case control study, we aim to identify breast cancer related risk factors associated with developing COVID-19 and describe outcomes of patients with breast cancer diagnosed with COVID-19. Methods: Women with breast cancer treated at the Medical College of Wisconsin and diagnosed with COVID-19 between March and December 2020 served as cases. Women with breast cancer without COVID-19 diagnosis within the same time frame were identified as potential controls. Controls were chosen by matching for age (≥60 vs <60), obesity (BMI <30 vs ≥30), county (Milwaukee vs suburban), race (white vs non-white) and diabetes mellitus (DM) with 3:1 matching planned. Univariate comparisons between cases and controls were done via Rao-Scott stratified chi-square test for categorical outcomes and stratified t-test for continuous variables. Conditional logistic regression was done to evaluate the joint effect of multiple characteristics on the odds of being a COVID-19 case. Results: Twenty-five cases and 77 controls were identified. All cases were fully matched by age, obesity, county, and race with 3 cases not able to be matched for DM. Mean age was 54.6 vs 54.9 (p=0.88), BMI 31.0 vs 31.6 (p=0.69), 48% lived in Milwaukee county and 68% were white (cases 24% black & 8% American Indian; controls 32% black). Regarding COVID outcomes, 24.0% (n=6) of cases were hospitalized, median length of stay was 2 days, 8% (n=2) needed oxygen, 4% (n=1) were intubated and 4% (n=1) died due to COVID-19. COVID-19 led to treatment delays in 40% of cases. On univariate analysis of cases vs controls, 64 vs 75% were ER/PR+ (p=0.31), 6.5 vs 5.2% HER2+ (p=0.34), and 9.0 vs 4.2% triple negative (p=0.10). There were no significant differences in breast cancer stage. At time of COVID diagnosis (or last clinic contact if control), 16 vs 14% had active disease (p=0.81), 72 vs 74% were on active treatment (p=0.85), with 21 vs 4% being on chemotherapy (p=0.007), and 44 vs 52% on endocrine therapy (p=0.49). On conditional logistic regression, being on active chemotherapy (OR 5.8, p=0.043) significantly increased the likelihood of developing COVID with a trend seen for triple negative disease (OR 2.8, p=0.12). Conclusions: In this matched case control study of patients with breast cancer, active chemotherapy was significantly associated with an increased likelihood of developing COVID-19 with a trend seen for triple negative disease. Rates of death due to COVID-19 were overall low. Our analysis was limited by small numbers and an inability to fully match patients for DM. These findings support continued strict precautions for those on active chemotherapy and warrants further analysis in those with triple negative disease.

Sign in / Sign up

Export Citation Format

Share Document